Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798477 | 0.98 | CYP1A2 (1.00) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| SCHEMBL1372 | 0.98 | CYP1A2 (1.00) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| SCHEMBL2645833 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Bromide SCHEMBL22418547 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Ammonia Solution, Strong SCHEMBL21805838 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Hydrochloric Acid SCHEMBL1595766 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| SCHEMBL2597843 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Hydrochloric Acid SCHEMBL2761 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Water SCHEMBL1475933 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| SCHEMBL31435659 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4530308-A1 | MULTI-CROSSLINKED GEL SYSTEM AND PRODUCT THEREOF, PREPARATION METHOD, AND USE | Shanghai Qisheng Biological Preparation Co., Ltd. (CN) | 2025-04-02 | — | — | EP | disclosed |
| WO-2024212266-A1 | MULTI-CROSSLINKED GEL SYSTEM AND PRODUCT THEREOF, PREPARATION METHOD, AND USE | 上海其胜生物制剂有限公司 | 2024-10-17 | — | — | WO | disclosed |
| CN-118767211-A | MMP response degradation type hydrogel and preparation method and application thereof | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 2024-10-15 | — | — | CN | disclosed |
| CN-111588847-A | Conjugate containing monophosphorylated lipid A and saccharide antigen and its prepn and application | 广州中医药大学(广州中医药研究院) | 2020-08-28 | — | — | CN | disclosed |
| US-8604205-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8604218-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2013-01-10 | — | — | US | disclosed |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2012-02-23 | — | — | US | disclosed |
| US-8071779-B2 | reduces intraocular pressure; primary open-angle glaucoma; effective to influence the actomyosin interactions by leading to cellular relaxation and alterations in cell-substratum adhesions | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2099457-A2 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | Inspire Pharmaceuticals, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2008-09-04 | — | — | US | disclosed |
| WO-2008077057-A2 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | CYP1A2 3738/4885CYP2D6 4418/4885ALDH1A1 3372/4885 |
| US-20120046275-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | CYP1A2 3738/4885CYP2D6 4418/4885ALDH1A1 3372/4885 |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | CYP1A2 3738/4885CYP2D6 4418/4885ALDH1A1 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.